What does this research mean for the field?

Henagliflozin significantly reduces albuminuria and uric acid levels over 12 weeks in Chinese patients with IgA nephropathy, while maintaining a favorable safety profile. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the real-world clinical efficacy and safety profile of henagliflozin in patients diagnosed with IgA nephropathy.

September 3, 2026Clinical Nephrology

Efficacy and safety of henagliflozin in IgA nephropathy: A real-world observational study from China

View Full Paper

Ask AI

Bookmark

Authors

YZYi Qian Zhang JWJun Xia Wu HTHai Yan Tu

Discussion

Member takes

Overview

Retrospective observational study demonstrates significant albuminuria reduction from henagliflozin in IgA nephropathy, highlighting its potential as a targeted kidney therapy.

Key Points

To evaluate the real-world clinical efficacy and safety profile of henagliflozin in patients diagnosed with IgA nephropathy.
Retrospectively evaluated 48 Chinese patients with IgA nephropathy receiving henagliflozin therapy over a 12-week follow-up period.
Assessed changes in the primary outcome of urinary albumin-to-creatinine ratio (UACR) alongside secondary endpoints including eGFR, serum creatinine, uric acid, serum albumin, and adverse events.
Henagliflozin significantly decreased UACR from baseline to week 12 (median 227.26 mg/g [IQR, 90.13–677.85] vs. 153.06 mg/g [IQR, 24.68–401.76]; p < 0.001), achieving a median 47.9% reduction and a ≥ 30% reduction in 64.6% of patients.
Serum uric acid dropped significantly (p < 0.001), while eGFR declined through week 8 (p ≤ 0.015) before returning to near-baseline values by week 12 (p = 0.055).
Observed adverse events included urinary tract infections in 5 patients, a serum creatinine increase of ≥ 50% in 1 patient, and hyperkalemia in 1 patient.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a9934cf636c6408cfa7c8dc https://doi.org/10.5414/cn111956

View Full Paper

Ask AI

Bookmark

September 3, 2026Clinical Nephrology

Efficacy and safety of henagliflozin in IgA nephropathy: A real-world observational study from China

View Full Paper

Ask AI

Bookmark

Authors

YZYi Qian Zhang JWJun Xia Wu HTHai Yan Tu

Discussion

Member takes

Overview

Retrospective observational study demonstrates significant albuminuria reduction from henagliflozin in IgA nephropathy, highlighting its potential as a targeted kidney therapy.

Key Points

To evaluate the real-world clinical efficacy and safety profile of henagliflozin in patients diagnosed with IgA nephropathy.
Retrospectively evaluated 48 Chinese patients with IgA nephropathy receiving henagliflozin therapy over a 12-week follow-up period.
Assessed changes in the primary outcome of urinary albumin-to-creatinine ratio (UACR) alongside secondary endpoints including eGFR, serum creatinine, uric acid, serum albumin, and adverse events.
Henagliflozin significantly decreased UACR from baseline to week 12 (median 227.26 mg/g [IQR, 90.13–677.85] vs. 153.06 mg/g [IQR, 24.68–401.76]; p < 0.001), achieving a median 47.9% reduction and a ≥ 30% reduction in 64.6% of patients.
Serum uric acid dropped significantly (p < 0.001), while eGFR declined through week 8 (p ≤ 0.015) before returning to near-baseline values by week 12 (p = 0.055).
Observed adverse events included urinary tract infections in 5 patients, a serum creatinine increase of ≥ 50% in 1 patient, and hyperkalemia in 1 patient.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a9934cf636c6408cfa7c8dc https://doi.org/10.5414/cn111956

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark